181 related articles for article (PubMed ID: 19010168)
1. Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors.
Barrera Pulido L; Alamo Martínez JM; Pareja Ciuró F; Gómez Bravo MA; Serrano Díez-Canedo J; Bernal Bellido C; Suárez Artacho G; García González I; Pascasio Acevedo JM; Bernardos Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2985-7. PubMed ID: 19010168
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of monotherapy with mycophenolate mofetil in liver transplantation.
Jiménez-Pérez M; Lozano Rey JM; Marín García D; Olmedo Martín R; de la Cruz Lombardo J; Rodrigo López JM
Transplant Proc; 2006 Oct; 38(8):2480-1. PubMed ID: 17097974
[TBL] [Abstract][Full Text] [Related]
3. Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction.
Ponton C; Vizcaíno L; Tomé S; Otero E; Molina E; Castroagudín JF; López-Lago A; Varo Pérez E
Transplant Proc; 2010 Mar; 42(2):656-9. PubMed ID: 20304216
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients.
Bilbao I; Castells L; Rojas L; Cancino J; Dopazo C; Castro E; Pou L; Andino R; Margarit C
Int Immunopharmacol; 2006 Dec; 6(13-14):1977-83. PubMed ID: 17161351
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis.
Manrique A; Jiménez C; Ortega P; Abradelo M; Gimeno A; Calvo J; Cambra F; -Sterup RL; Morales JM; Moreno E
Transplant Proc; 2008 Nov; 40(9):2962-4. PubMed ID: 19010160
[TBL] [Abstract][Full Text] [Related]
7. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
Raimondo ML; Dagher L; Papatheodoridis GV; Rolando N; Patch DW; Davidson BR; Rolles K; Burroughs AK
Transplantation; 2003 Jan; 75(2):186-90. PubMed ID: 12548120
[TBL] [Abstract][Full Text] [Related]
8. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin inhibitor withdrawal and conversion to mycophenolate mofetil and steroids in cardiac transplant recipients with chronic renal failure: a word of caution.
Groetzner J; Kaczmarek I; Schirmer J; Uberfuhr P; Gulbins H; Daebritz S; Meiser B; Reichart B
Clin Transplant; 2008; 22(5):587-93. PubMed ID: 18460000
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil promotes prolonged improvement of renal dysfunction after pediatric liver transplantation: experience of a single center.
Tannuri U; Gibelli NE; Maksoud-Filho JG; Santos MM; Pinho-Apezzato ML; Velhote MC; Ayoub AA; Silva MM; Maksoud JG
Pediatr Transplant; 2007 Feb; 11(1):82-6. PubMed ID: 17239128
[TBL] [Abstract][Full Text] [Related]
11. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation.
Créput C; Blandin F; Deroure B; Roche B; Saliba F; Charpentier B; Samuel D; Durrbach A
Liver Transpl; 2007 Jul; 13(7):1004-10. PubMed ID: 17600361
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction.
Koch RO; Graziadei IW; Schulz F; Nachbaur K; Königsrainer A; Margreiter R; Vogel W
Transpl Int; 2004 Oct; 17(9):518-24. PubMed ID: 15365603
[TBL] [Abstract][Full Text] [Related]
14. Safety of mycophenolate mofetil monotherapy in patients after liver transplantation.
Kamphues C; Bova R; Röcken C; Neuhaus R; Pratschke J; Neuhaus P; Neumann UP
Ann Transplant; 2009; 14(4):40-6. PubMed ID: 20009154
[TBL] [Abstract][Full Text] [Related]
15. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
16. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
Karie-Guigues S; Janus N; Saliba F; Dumortier J; Duvoux C; Calmus Y; Lorho R; Deray G; Launay-Vacher V; Pageaux GP
Liver Transpl; 2009 Sep; 15(9):1083-91. PubMed ID: 19718632
[TBL] [Abstract][Full Text] [Related]
17. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study.
Schlitt HJ; Barkmann A; Böker KH; Schmidt HH; Emmanouilidis N; Rosenau J; Bahr MJ; Tusch G; Manns MP; Nashan B; Klempnauer J
Lancet; 2001 Feb; 357(9256):587-91. PubMed ID: 11558484
[TBL] [Abstract][Full Text] [Related]
18. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
Groetzner J; Kaczmarek I; Landwehr P; Mueller M; Daebritz S; Lamm P; Meiser B; Reichart B
Eur J Cardiothorac Surg; 2004 Mar; 25(3):333-41. PubMed ID: 15019657
[TBL] [Abstract][Full Text] [Related]
19. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension.
Orlando G; Baiocchi L; Cardillo A; Iaria G; De Liguori Carino N; De Luca L; Ielpo B; Tariciotti L; Angelico M; Tisone G
Liver Transpl; 2007 Jan; 13(1):46-54. PubMed ID: 17154392
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction.
Cantarovich M; Tzimas GN; Barkun J; Deschênes M; Alpert E; Tchervenkov J
Transplantation; 2003 Jul; 76(1):98-102. PubMed ID: 12865793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
